Sepsis kills more people every year than breast cancer, prostate cancer, and AIDS combined. T2, founded in 2006, builds diagnostic tests and tools that help detect sepsis-causing pathogens faster than ever, and start life-saving treatments in time to make a difference. T2’s first test, for rapidly diagnosing deadly strains of candida, was approved by the FDA in 2014. In May 2018, the agency cleared T2’s bacteria panel, which IDs 50% of all bacterial bloodstream infections, 70% of all blood-culture species in the emergency department, and 90% of deadly ESKAPE pathogens. Both tests run on the T2DX Instrument, an automated desktop lab that returns results within 3 to 5 hours, versus 1 to 5 days for existing tests, which require waiting for a blood culture. The company has other tests in the pipeline, including for early detection of Lyme disease.